Celgene (NASDAQ:CELG) is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug, Otezla.

Despite Celgene's growing product lineup, shares are trading lower following the company's second quarter earnings report. As a result, investors are right to wonder if Celgene's winning streak is coming to an end.

Source: Celgene through June 11, 2014

In the following slideshow, you'll learn which of Celgene's drugs grew fastest and gain insight into whether shares are worth buying.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.